The ability to obtain high-quality radiobiological information about the interactions between tumor and healthy tissue, when using ionizing radiations, would contribute to the development of more effective and personalized radiotherapy treatments.
Frederic Zenhausern, PhD, MBA
Advertisement
Articles by Frederic Zenhausern, PhD, MBA
Advertisement
Latest Updated Articles
Platform Technology Development for Biologically Targeted Dosimetry and RadiotherapyPublished: October 12th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
4
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
5